Synthesis and biological evaluation of 2,6-di (furan-3-yl) anthracene-9, 10-dione as an inhibitor of human protein kinase CK2
Haidar, S.; Meyers, A.; Bollacke, A.; Jose, J.
Die Pharmazie 70(12): 772-776
2015
ISSN/ISBN: 0031-7144 PMID: 26817273 Document Number: 684163
Protein kinase CK2 is an emerging target for the therapeutic intervention in human diseases, in particular in cancer. Inhibitors of this enzyme are at current in clinical trials indicating its drug ability. Here we report on the synthesis of two derivatives of 2,6-diaryl-anthracene-9,10-dione, one of them, 2,6-di(furan-3-yl)anthracene-9,10-dione (3), turned out to be active towards CK2, and ATP competitive with an IC50 value of 2.35 μM and a K(i) value of 1.26 μM. Molecular modeling studies were performed to explain the binding affinity of compound 3 in comparison to emodin. These indicated that unlike emodin, compound 3 was not able to perform a hydrogen bond with Lys68, although the compound fits well in the active site of human CK2α, which explains the difference in the measured affinity between those two compounds.